Cadrenal Therapeutics, Inc. SEC filings CVKD
Cadrenal Therapeutics, Inc. has 277 filings in SEC EDGAR's recent list, going back to Jul 15, 2022. Its latest annual report, Form ARS, was filed on Aug 3, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 7, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-8 | Employee stock plan registration | Oct 8, 2026 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 7, 2026 | Oct 7, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Sep 29, 2026 | Sep 24, 2026 |
| S-8 | Employee stock plan registration | Sep 3, 2026 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 31, 2026 | Aug 31, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| DEFA14A | Additional proxy material | Aug 3, 2026 | — |
| ARS | Annual report to shareholders | Aug 3, 2026 | Dec 31, 2025 |
| DEF 14A | Proxy statement | Aug 3, 2026 | Sep 24, 2026 |
| PRE 14A | Preliminary proxy statement | Jul 23, 2026 | Jul 23, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jul 21, 2026 | Jul 21, 2026 |
| EFFECT | Filing | Jul 20, 2026 | — |
| 424B3 | Prospectus | Jul 20, 2026 | — |
| 8-K |
Current report
Officer or director change
|
Jul 17, 2026 | Jul 14, 2026 |
| D | Filing | Jul 15, 2026 | — |
| S-3 | Shelf registration | Jul 13, 2026 | — |
| 8-K |
Current report
Officer or director change
|
Jul 10, 2026 | Jul 7, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Jul 1, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 29, 2026 | Jun 25, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 18, 2026 | Jun 18, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 3, 2026 | May 28, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 30, 2026 | Apr 30, 2026 |
| EFFECT | Filing | Apr 29, 2026 | — |
| 424B3 | Prospectus | Apr 29, 2026 | — |
| CORRESP | Letter to the SEC | Apr 27, 2026 | — |
| UPLOAD | Letter from the SEC | Apr 27, 2026 | — |
| S-3 | Shelf registration | Apr 21, 2026 | — |
| D | Filing | Apr 6, 2026 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Change to shareholder rights
|
Apr 1, 2026 | Mar 31, 2026 |
| 424B5 | Prospectus supplement | Apr 1, 2026 | — |
| 10-K | Annual report | Mar 31, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 31, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Mar 12, 2026 | Mar 12, 2026 |
| 8-K |
Current report
Other events
|
Feb 24, 2026 | Feb 24, 2026 |
| 424B3 | Prospectus | Jan 2, 2026 | — |
| EFFECT | Filing | Dec 31, 2025 | — |
| D | Filing | Dec 31, 2025 | — |
| UPLOAD | Letter from the SEC | Dec 31, 2025 | — |
| CORRESP | Letter to the SEC | Dec 30, 2025 | — |
| S-1 | Registration statement | Dec 29, 2025 | — |
| 8-K |
Current report
Other events
|
Dec 23, 2025 | Dec 23, 2025 |
| 424B5 | Prospectus supplement | Dec 23, 2025 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Dec 16, 2025 | Dec 15, 2025 |
| 424B5 | Prospectus supplement | Dec 16, 2025 | — |
| 424B5 | Prospectus supplement | Dec 16, 2025 | — |
| 8-K |
Current report
Material agreement, Regulation FD disclosure, Other events
|
Dec 11, 2025 | Dec 10, 2025 |
| 8-K |
Current report
Officer or director change, Other events
|
Dec 1, 2025 | Nov 24, 2025 |
| 8-K |
Current report
Other events
|
Nov 18, 2025 | Nov 18, 2025 |
| 424B5 | Prospectus supplement | Nov 18, 2025 | — |
| 8-K |
Current report
Results of operations
|
Nov 10, 2025 | Nov 10, 2025 |
| 10-Q | Quarterly report | Nov 10, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Sep 24, 2025 | Sep 24, 2025 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure, Other events
|
Sep 15, 2025 | Sep 12, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2025 | Aug 11, 2025 |
| 10-Q | Quarterly report | Aug 11, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Other events
|
Aug 5, 2025 | Aug 5, 2025 |
| ARS | Annual report to shareholders | Jul 31, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Jul 31, 2025 | — |
| DEF 14A | Proxy statement | Jul 31, 2025 | Sep 24, 2025 |
| 8-K |
Current report
Officer or director change, Other events
|
Jul 18, 2025 | Jul 15, 2025 |
| 8-K |
Current report
Results of operations
|
May 8, 2025 | May 8, 2025 |
| 10-Q | Quarterly report | May 8, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Other events
|
Apr 17, 2025 | Apr 17, 2025 |
| 424B5 | Prospectus supplement | Apr 17, 2025 | — |
| 8-K |
Current report
Results of operations
|
Mar 13, 2025 | Mar 13, 2025 |
| 10-K | Annual report | Mar 13, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Material agreement, Other events
|
Mar 4, 2025 | Mar 3, 2025 |
| 8-K |
Current report
Officer or director change, Other events
|
Feb 7, 2025 | Feb 4, 2025 |
| S-8 | Employee stock plan registration | Feb 3, 2025 | — |
| S-8 | Employee stock plan registration | Dec 23, 2024 | — |
| 424B5 | Prospectus supplement | Dec 20, 2024 | — |
| 424B3 | Prospectus | Nov 25, 2024 | — |
| EFFECT | Filing | Nov 22, 2024 | — |
| CORRESP | Letter to the SEC | Nov 21, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 20, 2024 | — |
| S-3 | Shelf registration | Nov 14, 2024 | — |
| D | Filing | Nov 14, 2024 | — |
| 10-Q | Quarterly report | Nov 7, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 7, 2024 | Nov 7, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Change to shareholder rights, Other events
|
Nov 4, 2024 | Nov 1, 2024 |
| 424B5 | Prospectus supplement | Nov 4, 2024 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 24, 2024 | Oct 24, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 25, 2024 | Sep 25, 2024 |
| 8-K |
Current report
Listing notice
|
Sep 5, 2024 | Sep 5, 2024 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Other events
|
Aug 20, 2024 | Aug 19, 2024 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Other events
|
Aug 16, 2024 | Aug 16, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 8, 2024 | Aug 7, 2024 |
| 10-Q | Quarterly report | Aug 7, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 6, 2024 | Aug 6, 2024 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jul 31, 2024 | Jul 29, 2024 |
| DEFA14A | Additional proxy material | Jun 12, 2024 | — |
| ARS | Annual report to shareholders | Jun 11, 2024 | Dec 31, 2023 |
| DEF 14A | Proxy statement | Jun 11, 2024 | Jul 29, 2024 |
| PRE 14A | Preliminary proxy statement | May 29, 2024 | May 29, 2024 |
| 10-Q | Quarterly report | May 9, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Other events
|
May 9, 2024 | May 8, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 9, 2024 | Apr 9, 2023 |
| EFFECT | Filing | Apr 2, 2024 | — |
| POS AM | Post-effective amendment no. 1 to form s-1 | Apr 2, 2024 | — |
| EFFECT | Filing | Mar 20, 2024 | — |
| CORRESP | Letter to the SEC | Mar 18, 2024 | — |
| UPLOAD | Letter from the SEC | Mar 15, 2024 | — |
| S-8 | Employee stock plan registration | Mar 12, 2024 | — |
| S-3 | Shelf registration | Mar 12, 2024 | — |
| 8-K |
Current report
Material agreement
|
Mar 12, 2024 | Mar 11, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 11, 2024 | Mar 11, 2024 |
| 10-K | Annual report | Mar 11, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Listing notice
|
Mar 5, 2024 | Mar 5, 2024 |
| 8-K/A |
Amended current report
Listing notice
|
Feb 15, 2024 | Sep 6, 2023 |
| 8-K |
Current report
Officer or director change, Other events
|
Feb 12, 2024 | Feb 6, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2023 | Nov 9, 2023 |
| 10-Q | Quarterly report | Nov 9, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Oct 23, 2023 | Oct 20, 2023 |
| 8-K |
Current report
Listing notice
|
Sep 8, 2023 | Sep 6, 2023 |
| DEFA14A | Additional proxy material | Aug 31, 2023 | — |
| DEFA14A | Additional proxy material | Aug 31, 2023 | — |
| ARS | Annual report to shareholders | Aug 28, 2023 | Dec 31, 2022 |
| DEF 14A | Proxy statement | Aug 28, 2023 | Oct 20, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 18, 2023 | Aug 17, 2023 |
| 8-K |
Current report
Other events
|
Aug 16, 2023 | Aug 15, 2023 |
| 424B3 | Prospectus | Aug 16, 2023 | — |
| 8-K |
Current report
Results of operations
|
Aug 10, 2023 | Aug 10, 2023 |
| 10-Q | Quarterly report | Aug 10, 2023 | Jun 30, 2023 |
| 424B3 | Prospectus | Aug 1, 2023 | — |
| EFFECT | Filing | Jul 28, 2023 | — |
| CORRESP | Letter to the SEC | Jul 26, 2023 | — |
| UPLOAD | Letter from the SEC | Jul 26, 2023 | — |
| 8-K |
Current report
Officer or director change, Other events
|
Jul 24, 2023 | Jul 23, 2023 |
| S-1 | Registration statement | Jul 24, 2023 | — |
| D | Filing | Jul 18, 2023 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Jul 14, 2023 | Jul 12, 2023 |
| 8-K |
Current report
Officer or director change
|
May 26, 2023 | May 25, 2023 |
| 10-Q | Quarterly report | May 10, 2023 | Mar 31, 2023 |
| 8-K |
Current report
Results of operations
|
May 10, 2023 | May 10, 2023 |
| 10-K | Annual report | Mar 30, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 27, 2023 | Mar 27, 2023 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Officer or director change, Other events
|
Jan 25, 2023 | Jan 19, 2023 |
| S-8 | Employee stock plan registration | Jan 24, 2023 | — |
| 424B4 | Prospectus | Jan 23, 2023 | — |
| 424B4 | Prospectus | Jan 23, 2023 | — |
| SEC STAFF LETTER | Filing | Jan 20, 2023 | — |
| CERT | Filing | Jan 20, 2023 | — |
| EFFECT | Filing | Jan 19, 2023 | — |
| 8-A12B | Registration of certain classes of securities | Jan 17, 2023 | — |
| CORRESP | Letter to the SEC | Jan 17, 2023 | — |
| CORRESP | Letter to the SEC | Jan 17, 2023 | — |
| S-1/A | Amended registration statement | Jan 17, 2023 | — |
| S-1/A | Amended registration statement | Dec 28, 2022 | — |
| CORRESP | Letter to the SEC | Dec 8, 2022 | — |
| S-1/A | Amended registration statement | Dec 8, 2022 | — |
| D | Filing | Dec 8, 2022 | — |
| UPLOAD | Letter from the SEC | Dec 8, 2022 | — |
| S-1/A | Amended registration statement | Dec 6, 2022 | — |
| S-1/A | Amended registration statement | Oct 17, 2022 | — |
| CORRESP | Letter to the SEC | Oct 17, 2022 | — |
| UPLOAD | Letter from the SEC | Oct 13, 2022 | — |
| SEC STAFF LETTER | Filing | Oct 12, 2022 | — |
| S-1/A | Amended registration statement | Oct 11, 2022 | — |
| CORRESP | Letter to the SEC | Sep 22, 2022 | — |
| S-1 | Registration statement | Sep 22, 2022 | — |
| DRSLTR | Filing | Sep 2, 2022 | — |
| DRS/A | Filing | Sep 2, 2022 | — |
| UPLOAD | Letter from the SEC | Aug 30, 2022 | — |
| DRSLTR | Filing | Aug 23, 2022 | — |
| DRS/A | Filing | Aug 23, 2022 | — |
| UPLOAD | Letter from the SEC | Aug 11, 2022 | — |
| D | Filing | Jul 25, 2022 | — |
| DRS | Filing | Jul 15, 2022 | — |
Showing 171 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CVKD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Ponte Vedra, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1937993
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.